Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
Business Wire•28/07/2026•07:45 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.